Ellen Caswell, MD
Endocrinology, Diabetes & Metabolism · Gulfport, MSNPI 1487018420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 278 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,223, 4.2 times the $292 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MS, where the typical reported total is $4,678.
Across 278 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$956
- Abbott$713
- Xeris Pharmaceuticals, Inc.$630
- Amgen$542
- Novo Nordisk$463
- Lilly USA, LLC$370
- plus $1K from 27 others
What the payments were for
- Food & beverage$4,89496%
- Education$230%
- Other$1954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 48 | $956 |
| Abbott | 40 | $713 |
| Xeris Pharmaceuticals, Inc. | 36 | $630 |
| Amgen | 30 | $542 |
| Novo Nordisk | 26 | $463 |
| Lilly USA, LLC | 22 | $370 |
| Dexcom, Inc. | 14 | $234 |
| AstraZeneca(2 entities) | 4 | $132 |
| Boehringer Ingelheim | 3 | $122 |
| Lifescan, Inc. | 7 | $112 |
| Insulet Corporation | 4 | $78 |
| AbbVie | 4 | $69 |
| Corcept Therapeutics | 4 | $68 |
| Medtronic | 4 | $66 |
| GRT US Holding, Inc. | 4 | $65 |
| Novartis | 3 | $62 |
| Radius Health, Inc. | 3 | $53 |
| Ultragenyx Pharmaceutical Inc. | 3 | $52 |
| Eisai Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Madrigal Pharmaceuticals | 2 | $33 |
| Pfizer | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Recordati_rare_diseases_inc. | 1 | $23 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| BETA Bionics, Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE COPILOT$165
- EVENITY$125
- Kerendia$125
How this compares
$5,112 in reported general payments places this provider in the 50th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $210,637 |
| JardianceEmpagliflozin | 138 | $121,030 |
| MounjaroTirzepatide | 100 | $118,981 |
| RybelsusSemaglutide | 80 | $99,415 |
| TymlosAbaloparatide | 29 | $76,425 |
| FarxigaDapagliflozin Propanediol | 73 | $48,789 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $42,233 |
| ProliaDenosumab | 22 | $38,850 |
| TrulicityDulaglutide | 29 | $35,078 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $34,543 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $33,051 |
| JanuviaSitagliptin Phosphate | 31 | $32,019 |
| KerendiaFinerenone | 34 | $29,184 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $16,645 |
| Humalog Kwikpen U-100Insulin Lispro | 33 | $16,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $463 | $314,508259 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $370 | $156,429155 claims |
| Boehringer IngelheimJardiance, Tradjenta | $122 | $137,341162 claims |
| Radius Health, Inc.Tymlos | $53 | $76,42529 claims |
| AstraZenecaFarxiga | $132 | $48,78973 claims |
| AmgenProlia | $542 | $38,85022 claims |
| MerckJanuvia | $11 | $32,01931 claims |
| BayerKerendia | $956 | $29,18434 claims |
| AbbVieSynthroid, Armour Thyroid | $69 | $10,161147 claims |
| Sanofi-aventis U.S. LLCLantus | $34 | $3,34537 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $2,443322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Gulfport
- Mark BorcheltGulfport$722K
- Eric DyessJackson$885K
- Honey EastJackson$721K
- Ben SealeJackson$623K
- Jeremy TaylorMadison$271K
- Amanda SchieferJackson$204K
- Delali BlavoSouthaven$148K
- Richard GallowayHattiesburg$109K
- James PowellHattiesburg$88K
- John SistrunkJackson$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.